Skip to content

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04552964
Acronym
CONDORE
Enrollment
31
Registered
2020-09-17
Start date
2020-09-25
Completion date
2021-04-27
Last updated
2021-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Brief summary

Glaucoma is one of the most common chronic pathologies and affects several millions patients. Among these, many have a poorly controlled glaucoma, damaging vision and leading to blindness. One between principal reasons for poor glaucoma medication adherence is forgetfulness. To improve this issue, digital tools may benefit both ophthalmologists and patients by monitoring eye drop administration.

Interventions

Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire

Sponsors

Laboratoires Thea
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

This will be a single centre, single-arm, prospective pilot study.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient \> 18 years old, both genders 2. Diagnosed with glaucoma, with controlled IOP (\<18mmHg) 3. Currently receiving a topical glaucoma treatment 4. Receiving a multitherapy a fixed combination of dorzolamide-timolol, preservative-free. 5. Patient willing to participate in the study. 6. Patient familiar with a smartphone and its applications

Exclusion criteria

1. Patient with any eye condition in addition to glaucoma requiring expected additional treatment 2. Patient with an ongoing or known history of ocular allergy and/or uveitis and/or viral infection and or ocular infection. 3. Patient who underwent intraocular surgery within the past 3 months or scheduled to undergo intraocular surgery within the next 3 months 4. Patient with best-correct visual acuity \<20/70 in the better seeing eye 5. Patient whose drop administration is performed by someone else 6. Alcohol addiction and/or heavy smoker, according to the investigator's judgement. 7. Patient inability to understand the study procedures or to give informed consent. 8. Non-compliant patient (e.g., not willing to attend a visit; way of life interfering with compliance). 9. Participation in this study at the same time as in another clinical study. 10. Patient being institutionalized because of legal or regulatory order, inmate of psychiatric wards, prison or state institutions, or employee of the study sites or of the sponsor's company. 11. Patient not covered by the government health care scheme of the country in which he/she is living (if applicable). 12. Women of childbearing potential, pregnant or breastfeeding: Childbearing potential is defined as a woman who is not using a reliable method of contraception (oral contraceptive, intrauterine device, subcutaneous contraceptive implant, vaginal ring, patch) or is not surgically sterilized.

Design outcomes

Primary

MeasureTime frameDescription
Global patient satisfactionWeek 9Global patient satisfaction (Patient satisfaction questionnaire)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026